<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/273BA583-03B3-4054-9371-E37F72293F80"><gtr:id>273BA583-03B3-4054-9371-E37F72293F80</gtr:id><gtr:name>Apellis Pharmaceutical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/358C5117-9DBE-4BD7-A038-90B4FEECE45A"><gtr:id>358C5117-9DBE-4BD7-A038-90B4FEECE45A</gtr:id><gtr:name>University of Utrecht</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/63AEA72C-8DC5-4E1E-84F7-FBE69D677A67"><gtr:id>63AEA72C-8DC5-4E1E-84F7-FBE69D677A67</gtr:id><gtr:name>Centro de Investigaciones Biol?gicas (CIB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B52848EB-6923-4123-A367-0D33966FD9FC"><gtr:id>B52848EB-6923-4123-A367-0D33966FD9FC</gtr:id><gtr:name>Albert-Ludwigs University Freiburg</gtr:name><gtr:address><gtr:line1>Albert-Ludwigs University</gtr:line1><gtr:line2>Werthmannplatz 1</gtr:line2><gtr:line3>D-79085 Freiburg1</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5982AEC1-3C31-4F8A-8FE5-C52D859BFD9C"><gtr:id>5982AEC1-3C31-4F8A-8FE5-C52D859BFD9C</gtr:id><gtr:name>University of Luebeck</gtr:name><gtr:address><gtr:line1>University of Luebeck</gtr:line1><gtr:line2>Ratzeburger Allee 160</gtr:line2><gtr:postCode>D-23538</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/273BA583-03B3-4054-9371-E37F72293F80"><gtr:id>273BA583-03B3-4054-9371-E37F72293F80</gtr:id><gtr:name>Apellis Pharmaceutical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/358C5117-9DBE-4BD7-A038-90B4FEECE45A"><gtr:id>358C5117-9DBE-4BD7-A038-90B4FEECE45A</gtr:id><gtr:name>University of Utrecht</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/63AEA72C-8DC5-4E1E-84F7-FBE69D677A67"><gtr:id>63AEA72C-8DC5-4E1E-84F7-FBE69D677A67</gtr:id><gtr:name>Centro de Investigaciones Biol?gicas (CIB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B52848EB-6923-4123-A367-0D33966FD9FC"><gtr:id>B52848EB-6923-4123-A367-0D33966FD9FC</gtr:id><gtr:name>Albert-Ludwigs University Freiburg</gtr:name><gtr:address><gtr:line1>Albert-Ludwigs University</gtr:line1><gtr:line2>Werthmannplatz 1</gtr:line2><gtr:line3>D-79085 Freiburg1</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5982AEC1-3C31-4F8A-8FE5-C52D859BFD9C"><gtr:id>5982AEC1-3C31-4F8A-8FE5-C52D859BFD9C</gtr:id><gtr:name>University of Luebeck</gtr:name><gtr:address><gtr:line1>University of Luebeck</gtr:line1><gtr:line2>Ratzeburger Allee 160</gtr:line2><gtr:postCode>D-23538</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6A7AEE45-7C3C-46BC-B0FD-2BD6B17DBBB9"><gtr:id>6A7AEE45-7C3C-46BC-B0FD-2BD6B17DBBB9</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Cope</gtr:surname><gtr:orcidId>0000-0001-6735-5496</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6EF3CAD6-8066-4EB4-8BE0-5D4CDCC26738"><gtr:id>6EF3CAD6-8066-4EB4-8BE0-5D4CDCC26738</gtr:id><gtr:firstName>Claudia</gtr:firstName><gtr:otherNames>Marlis</gtr:otherNames><gtr:surname>Kemper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3EC4030F-93FC-40A8-8411-800860C10E6B"><gtr:id>3EC4030F-93FC-40A8-8411-800860C10E6B</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Lavender</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1002165"><gtr:id>22D987F9-0521-4EC5-8030-5135DD0EA9C6</gtr:id><gtr:title>The molecular and cellular basis of complement-mediated T helper 1 (TH1) differentiation and regulation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002165</gtr:grantReference><gtr:abstractText>A group of white cells called T lymphocytes forms a major part of our immune system and self-defence against dangerous infections. T lymphocytes seek and destroy pathogen-infected tissue and cells. However, these lymphocytes sometimes wrongly recognise proteins on our own tissues: This can cause destructive conditions such as rheumatoid arthritis and multiple sclerosis. Because T lymphocytes have such potent ability to be either beneficial or dangerous, their function is tightly regulated. To fight infections, these cells produce a cytokine called IFN-gamma. One of the control mechanisms to regulate the production of IFN-gamma is the induction of another cytokine, IL-10, within the same T cell, which then ?shuts down? IFN-gamm; expression. However, how exactly the T cell regulates the appropriate production of IFN-gamma vs. IL-10 is not understood. We have recently discovered that a protein called CD46 (which is present on the surface of T lymphocytes) is an important trigger for the switching of IFN-gamma to IL-10 in human T cells by sending appropriate signals into the cell. In addition, we have made the exciting observation that our finding is important for understanding a major human disease, rheumatoid arthritis (RA): We observed that the CD46 signals transduced do not work properly in T cells from RA patients (they do not shut down IFN-gamma). We now aim at finding out what exactly happens on a molecular level inside the cells when CD46 is activated on the cell surface of a healthy T cell. Understanding these ?signaling events? within healthy T cells will then allow us to compare those to data to signals from RA patients? T cells and define exactly were things ?are going wrong?. The understanding of this induction pathway will then lay the groundwork to understand the pathogenesis of RA and thereby to develop better diagnostics and therapies. The main investigator (CK) of this study is a leading authority in the functions of CD46 and regulatory lymphocytes. She has recently relocated from the US to the MRC Centre for Transplantation at King?s College and will now collaborate with outstanding experts (AC) in the RA field and in cytokine regulation (PL) on this project. Because King?s emphasizes strongly the crosstalk between basic research and clinical/patient work, CK will be in a position to rapidly interpret the findings for patient benefit. The proposed funding will help establish this promising body of work in the UK.</gtr:abstractText><gtr:technicalSummary>Control of IFN-gamma-secreting CD4+ TH1 effector T cells is vital for the prevention of immunopathologies during and after infection and unwanted responses against self or innocuous antigens. IL-10 is a key cytokine mediating negative control of TH1 responses. Although IL-10 is produced by several cell types and, thus, many cells can ?extrinsically? suppress TH1 responses, a novel concept now suggests that the major TH1 suppression pathway may be represented by ?intrinsic? regulation: A negative feedback loop working via the timely coinduction of IL-10 in addition to IFN-gamma within TH1 cells. Although the importance of IFN-gamma to IL-10 switching is acknowledged, the molecular pathways regulating these two cytokines in TH1 cells are undefined. 
We identified the complement regulator CD46 as key receptor in regulating IFN-gamma and IL-10 production in TH1 cells (Cardone et. al, Nature Immunology, 2010). We demonstrated that CD46 not only drives IFN-gamma production and effector function of human TH1 cells but also induces the switch to IL-10 secretion and into the regulatory phase in an IL-2-dependent fashion: In the presence of low IL-2 CD46 induces almost exclusively IFN-gamma+ effector TH1 cells while high environmental IL-2 then switches these cells from an IFN-gamma+/IL-10+ intermediate finally into IL-10+ T cells, with both of the latter populations being suppressive. Importantly, we showed that this CD46-mediated switch is defective in rheumatoid arthritis (RA) patients: T cells from these patients lack the IL-10+ cell subpopulation, produce up to 20 times more IFN-gamma compared to those from healthy individuals and never enter the regulatory phase. Thus, we hypothesize that CD46-transduced signals play a vital role in the induction and resolution of human TH1 responses and that disturbance in CD46 signals is associated with RA. This application aims now at delineating the molecular signals regulating IFN-gamma/IL-10 switching in human TH1 cells. We propose that each of the CD46/IL-2-mediated sequential phases in the TH1 cell ?life cycle? (IFN-gamma+, the IFN-gamma+/IL-10+ and IL-10+) are defined by the expression of specific genes and miRNAs as well as distinct changes in the chromatin environment. We will identify those changes and generate a comprehensive transcriptomic signature of each of the TH1 induction and regulation phases present in T cells from healthy donors (in comparison with T cells from RA patients). This ?molecular landscape? will then provide an experimental framework to identify single proteins and pathways required for IFN-gamma/IL-10 switching, and to uncover the defect(s) in TH1 regulation in RA.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-12</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>857584</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Characterization of the molecular crosstalk between CD46 and IL-2R during Th1 induction and regulation</gtr:description><gtr:id>CE4D6B15-F10B-48DB-BA0A-306E2DABD182</gtr:id><gtr:impact>U.S. Provisional Patent Application U.S.S.N.61/868,016 with full patent application pending</gtr:impact><gtr:partnerContribution>Our collaborators contribute with reagents, expertise and pertinent experiments. Results and subsequent experimental strategies are discussed during regular meetings.</gtr:partnerContribution><gtr:piContribution>We have developed successfully an approach to differentiate between the CD46 and the IL-2R-mediated signals in Th1 induction and are using this approach to define the single contributions as well as the crosstalk of these receptor-mediated pathways in IFN-gamma induction and IL-10 switching.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Rheuamtology</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>E9EE066E-ED53-4D06-B3B0-CC24E1602A45</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>The crosstalk beteen complement and the IL-2 receptor system</gtr:description><gtr:id>AE489818-7006-4786-BDC3-13BA3199E9FE</gtr:id><gtr:impact>None yet. Manuscript submission is expected at the end of 2015.</gtr:impact><gtr:partnerContribution>This partner contributes unique expertise and reagents (mouse strains) to the study</gtr:partnerContribution><gtr:piContribution>We have observed a new function for certain complement components in the regulation of the IL-2 receptor family system and performing the cell biology experiments to dissect those</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Division of Medicine</gtr:department><gtr:description>The role of immmune cell-derived complement in Scleroderma</gtr:description><gtr:id>504D9FC6-6F66-4993-958E-FE8CFA14DF29</gtr:id><gtr:impact>We expect outputs and outcomes by the middle/end of 2014</gtr:impact><gtr:partnerContribution>Delivery of Scleroderma patients samples, collaborative experiments, exchange of data, reagents and ideas.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments, training of a postdoctoral fellow from Dr. Abraham's laboratory (Dr. Sandra Guerra) in T cell-related techniques with emphasis on the roles of T cell-expressed complement receptors in Scleroderma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>University Medical Center</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>104849D5-2B2E-4E81-95F1-E57EB3F86C53</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nagoya University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>School of Medicine Nagoya</gtr:department><gtr:description>The role of of novel in human T cell Biology</gtr:description><gtr:id>C0BDF35C-76F0-45E7-B849-389C41EFE806</gtr:id><gtr:impact>Data generation is progressing well, we expect a first collaborative paper in 2014.</gtr:impact><gtr:partnerContribution>Dr. Takahashi's group provided the receptor KO mouse strain to us and is performing at the same time experiments to asses the role of this molecule in vivo in infection models.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on the role of a novel complement receptor in human T cell responses. We are assessing the novel function of this molecule mostly on human T cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel (Universit?t Basel)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>The role of CD46 in key T cell metabolic pathways</gtr:description><gtr:id>B2AFEEE0-00E4-446F-9B61-961058906465</gtr:id><gtr:impact>Manuscript is under review in a high impact journal.</gtr:impact><gtr:partnerContribution>This group has performed all experiments in conjunction with T cell metabolic measurements and had critical and equal intellectual input into this project.</gtr:partnerContribution><gtr:piContribution>We generated preliminary data on which the study is based and performed the core T cell activation experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The crosstalk beteen complement and the IL-2 receptor system</gtr:description><gtr:id>1EB3F68F-9E1D-4856-B835-9577EE54B2AE</gtr:id><gtr:impact>None yet. Manuscript submission is expected at the end of 2015.</gtr:impact><gtr:partnerContribution>This partner contributes unique expertise and reagents (mouse strains) to the study</gtr:partnerContribution><gtr:piContribution>We have observed a new function for certain complement components in the regulation of the IL-2 receptor family system and performing the cell biology experiments to dissect those</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Structural analyses on the role of complement and Notch system interactions</gtr:description><gtr:id>BFD1AADA-19AA-470C-980E-933971DD54B6</gtr:id><gtr:impact>Publication in a high impact journal (Nature Immunology 2012) and an ongoing collaboration with additional novel data likely also publishable in a high impact journal.</gtr:impact><gtr:partnerContribution>Our collaborators provide the protein and biochemical 'side' of this project.</gtr:partnerContribution><gtr:piContribution>We are contributing the functional assays and data on the in vivo importance of the complement/Notch system crosstalk</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Centre for Immune Regulation</gtr:department><gtr:description>The role of C5 in the negative regulation of human Th1 immunity</gtr:description><gtr:id>2F5CE102-AE64-4A3A-BE46-31C8C3904FD5</gtr:id><gtr:impact>A manuscript is in preparation. The data from this collaboration were presented at the 14th European meetimg on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:partnerContribution>Delivery of rare C5-deficient patient samples, collaborative experiments, exchange of reagents</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on new functions of C5aR and C5L2 in human T cell biology, exchange of ideas and data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Utrecht</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>University Medical Center</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>07D46B21-B994-477F-B05D-B535334C885E</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine KCL</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Immunology, Infection &amp; Inflammatory Disease (DIIID)</gtr:department><gtr:description>Characterization of the molecular crosstalk between CD46 and IL-2R during Th1 induction and regulation</gtr:description><gtr:id>6513C8C9-D44C-476C-B1F8-456F91B4C027</gtr:id><gtr:impact>U.S. Provisional Patent Application U.S.S.N.61/868,016 with full patent application pending</gtr:impact><gtr:partnerContribution>Our collaborators contribute with reagents, expertise and pertinent experiments. Results and subsequent experimental strategies are discussed during regular meetings.</gtr:partnerContribution><gtr:piContribution>We have developed successfully an approach to differentiate between the CD46 and the IL-2R-mediated signals in Th1 induction and are using this approach to define the single contributions as well as the crosstalk of these receptor-mediated pathways in IFN-gamma induction and IL-10 switching.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Academic Rheumatology</gtr:department><gtr:description>Assessment of CD46-mediated IFN-gamma to IL-10 switching as diagnostic tool for TNF weaning in RA</gtr:description><gtr:id>E33CCFB5-6970-436B-B4F6-0E16CB9733F9</gtr:id><gtr:impact>Ongoing. First data expected end 2013</gtr:impact><gtr:partnerContribution>My partners contribute with the provision of clinical patients samples, data analyses etc.</gtr:partnerContribution><gtr:piContribution>Development of an in vivo assay to assess if RA patents can be tapered of anti-TNF therapy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centro de Investigaciones Biol?gicas (CIB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Molecular Pathology Group</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>EF74A0AB-86AC-4E5C-B1D4-AA4D1A6D952F</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of L?beck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute for Inflammation Research</gtr:department><gtr:description>Dissecting the roles of anaphylatoxins in human Th1 induction and regulation</gtr:description><gtr:id>B6FDB6B5-2445-43DA-83A7-90EE8E442317</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:partnerContribution>Our collaborators will provide unique reagents (proteins, inhibitors etc.) as well as pertinent patient blood samples (all ethics in place) and validation of new findings for in vivo importance then in mouse models.</gtr:partnerContribution><gtr:piContribution>We have developed a hypothesis and preliminary data on novel roles for several complement activation fragments in human Th1/Th2 regulation and will provide further cell-based assay data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Randall Division of Cell &amp; Molecular Biophysics</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>FAABBB8D-FDE5-4140-8607-1A8EA61B4630</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Department of Immunology and Transfusion Medicine</gtr:department><gtr:description>Dissecting the roles of anaphylatoxins in human Th1 induction and regulation</gtr:description><gtr:id>A412C6C6-0274-4D6A-803C-4A8E9EB48134</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:partnerContribution>Our collaborators will provide unique reagents (proteins, inhibitors etc.) as well as pertinent patient blood samples (all ethics in place) and validation of new findings for in vivo importance then in mouse models.</gtr:partnerContribution><gtr:piContribution>We have developed a hypothesis and preliminary data on novel roles for several complement activation fragments in human Th1/Th2 regulation and will provide further cell-based assay data.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine (UPenn)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology and Laboratory Medicine</gtr:department><gtr:description>Dissecting the roles of anaphylatoxins in human Th1 induction and regulation</gtr:description><gtr:id>44BA0368-89A2-4B6F-9B5B-0BEED5E7AE99</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:partnerContribution>Our collaborators will provide unique reagents (proteins, inhibitors etc.) as well as pertinent patient blood samples (all ethics in place) and validation of new findings for in vivo importance then in mouse models.</gtr:partnerContribution><gtr:piContribution>We have developed a hypothesis and preliminary data on novel roles for several complement activation fragments in human Th1/Th2 regulation and will provide further cell-based assay data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Apellis Pharmaceutical</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Therapeutic targeting of complement receptors</gtr:description><gtr:id>B4AB3C0F-CFB6-419C-83F5-4D1D7D22A24C</gtr:id><gtr:impact>U.S. Provisional Patent Application U.S.S.N.61/868,016 with full patent application pending</gtr:impact><gtr:partnerContribution>Generation and provision of human complement receptor targeted reagents (agonists and antagonists).</gtr:partnerContribution><gtr:piContribution>Experiments on the role of specific complement receptors in T cell responses in in vivo disease models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Complement and Inflammation Research</gtr:department><gtr:description>Characterization of a novel convertase-independent intracellular complement activation pathway</gtr:description><gtr:id>7D6B9C90-D5FC-4EE1-953C-BBFB23235F3C</gtr:id><gtr:impact>Manuscript published in 'Immunity'. Currently working on a follow-up manuscript.</gtr:impact><gtr:partnerContribution>Our collaborators are contributing with expertise, reagents, crystal structure generation and pertinent animal models to this study.</gtr:partnerContribution><gtr:piContribution>We have discovered a novel intracellular complement activation pathway and are spear-heading the further characterization of this pathway in collaboration with the listed investigators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1540000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust New Investigator</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>33D348BA-33BB-4642-812E-7DAD12161B4D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>680000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>BTCURE: Understanding aberrant adaptive immunity mechanisms in human chronic immune-mediated diseases: rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>72A737A7-7E3D-44F5-8C70-EE93DABFC18F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We discovered that C5L2 on the surface of all T cells, monocytes and stem cells can impact in cell function and differentiation. This provisional patent protects the development of a wide range of specific C5L2 agonistic and antagonistic reagents (chemical, petides, antibodies etc. for a wide range of applications (human dieseases, transplantation, stem cell development etc.)</gtr:description><gtr:id>70193D87-02EE-4693-A361-BCA25CCA69E6</gtr:id><gtr:impact>Expected in 2014</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>US Provisional patent application</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS AND METHODS RELATING TO C5L2 (Inventor: Claudia Kemper, co-applicants: KCL and Apellis)</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Renal Project Board Steering Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>94567EA1-1BF7-47B7-8CF1-79368CBC3621</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have generated gene array analyses from rare patients with deficiency in CD46 expression (non-activated and 2 hr time point post TCR, TCR and CD28 and TCR and CD46 activation).</gtr:description><gtr:id>31757C5F-4953-43E2-A02F-ADCB79BDDC89</gtr:id><gtr:impact>Data are in the progress of being published on OA data bases</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Gene arrays of T cells from patients with CD46 deficiency</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This output describes in detail the cleavage and activation of human C3 by cathepsin L - a method discovered in my laboratory.</gtr:description><gtr:id>A5C2C81E-A9AA-4B67-9426-5B6160E8FA38</gtr:id><gtr:impact>Not yet measurable</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Protocol for the proteolytic cleavage of C3 by cathepsin L</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.bio-ptotocol.org/e1205</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/657DC799-8780-46D4-9B71-0BCBA40058BE"><gtr:id>657DC799-8780-46D4-9B71-0BCBA40058BE</gtr:id><gtr:title>The Th1 life cycle: molecular control of IFN-? to IL-10 switching.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c48efd814cd453812cf26d64a362f18"><gtr:id>2c48efd814cd453812cf26d64a362f18</gtr:id><gtr:otherNames>Cope A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/711A92A8-0CF0-4A95-83CE-18457EF57547"><gtr:id>711A92A8-0CF0-4A95-83CE-18457EF57547</gtr:id><gtr:title>Detection of cell membrane-bound CD46 using flow cytometry.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C65E6841-B18E-472A-90F6-C325BABAE998"><gtr:id>C65E6841-B18E-472A-90F6-C325BABAE998</gtr:id><gtr:title>Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7140ca04699a825eec70db4f7cfc3903"><gtr:id>7140ca04699a825eec70db4f7cfc3903</gtr:id><gtr:otherNames>Ghannam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF88F08F-0185-45CC-B4A3-C201D9E182C3"><gtr:id>AF88F08F-0185-45CC-B4A3-C201D9E182C3</gtr:id><gtr:title>Novel roles of complement in T effector cell regulation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c5a2f245b6fb067c6787d3c23ab380a"><gtr:id>4c5a2f245b6fb067c6787d3c23ab380a</gtr:id><gtr:otherNames>Heeger PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/076FB632-384D-4945-BF8B-55DCD1FB10BC"><gtr:id>076FB632-384D-4945-BF8B-55DCD1FB10BC</gtr:id><gtr:title>Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63fdf10576926ea41cafd72d082d6a1"><gtr:id>f63fdf10576926ea41cafd72d082d6a1</gtr:id><gtr:otherNames>Liszewski MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56D209A3-6A74-4434-9016-B9D5EFF6700C"><gtr:id>56D209A3-6A74-4434-9016-B9D5EFF6700C</gtr:id><gtr:title>Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCFD7D02-809A-4E62-9F3A-B0C4BDD5E1BE"><gtr:id>CCFD7D02-809A-4E62-9F3A-B0C4BDD5E1BE</gtr:id><gtr:title>The CD46-Jagged1 interaction is critical for human TH1 immunity.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8675b34ec9571215a904cc99c2130cdf"><gtr:id>8675b34ec9571215a904cc99c2130cdf</gtr:id><gtr:otherNames>Le Friec G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D11BE6A-85C3-4B14-9EE3-3711CD00DAEE"><gtr:id>6D11BE6A-85C3-4B14-9EE3-3711CD00DAEE</gtr:id><gtr:title>Complement nomenclature 2014.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D2ECA84F-0D8E-4698-9A57-C3E3B280ACCD"><gtr:id>D2ECA84F-0D8E-4698-9A57-C3E3B280ACCD</gtr:id><gtr:title>The role of complement in CD4? T cell homeostasis and effector functions.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A900CDFA-26C5-4C15-B6B1-4FA3A41D01FE"><gtr:id>A900CDFA-26C5-4C15-B6B1-4FA3A41D01FE</gtr:id><gtr:title>CD46: the 'multitasker' of complement proteins.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43405bdee47846dd21c53267cfab3fd4"><gtr:id>43405bdee47846dd21c53267cfab3fd4</gtr:id><gtr:otherNames>Yamamoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73D6C9E7-18F7-49BE-9714-CB5D4B0BE86F"><gtr:id>73D6C9E7-18F7-49BE-9714-CB5D4B0BE86F</gtr:id><gtr:title>C3a modulates IL-1? secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a316adfc796e81a38c1044af9c04fdd4"><gtr:id>a316adfc796e81a38c1044af9c04fdd4</gtr:id><gtr:otherNames>Asgari E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F153F328-A64C-4C6C-A4FD-13F37858802D"><gtr:id>F153F328-A64C-4C6C-A4FD-13F37858802D</gtr:id><gtr:title>Novel roles for complement receptors in T cell regulation and beyond.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB687B6F-2CBD-47E0-ACBA-D45BDE144337"><gtr:id>BB687B6F-2CBD-47E0-ACBA-D45BDE144337</gtr:id><gtr:title>A complement a day keeps the Fox(p3) away.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8675b34ec9571215a904cc99c2130cdf"><gtr:id>8675b34ec9571215a904cc99c2130cdf</gtr:id><gtr:otherNames>Le Friec G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002165</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>